Ciprofloxacin Ethyl Ester

Ciprofloxacin Ethyl Ester

SCHEMBL6779201

CCOC(=O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.74
ALDH1A1 P00352 6/20 0.74
HPGD P15428 5/20 0.74
HSD17B10 Q99714 5/20 0.74
LMNA P02545 3/20 0.74
CYP1A2 P05177 1/20 0.74
TOP2A P11388 1/20 0.74
CYP2C9 P11712 1/20 0.74
TOP2B Q02880 1/20 0.74
MAPT P10636 1/20 0.62
BRD4 O60885 1/20 0.57
TSHR P16473 1/20 0.57
HTT P42858 1/20 0.57
CYP2J2 P51589 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
TP53 P04637 1/20 0.53
CASP3 P42574 1/20 0.53
CASP9 P55211 1/20 0.53
BAX Q07812 1/20 0.53
PIK3CG P48736 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1706011 0.91 KDM4E (0.69) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL14616028 0.90 KDM4E (0.68) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL29576777 0.90 ALDH1A1 (0.66) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL9638922 0.90 ALDH1A1 (0.66) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL8983611 0.89 KDM4E (0.78) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL9500971 0.89 KDM4E (0.81) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL29475791 0.89 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10LMNA
SCHEMBL8038539 0.89 KDM4E (0.79) KDM4EALDH1A1HPGDHSD17B10LMNA
Hydrochloric Acid SCHEMBL9158179 0.88 KDM4E (0.68) KDM4EALDH1A1HPGDHSD17B10LMNA
Hydrochloric Acid SCHEMBL9152004 0.88 KDM4E (0.68) KDM4EALDH1A1HPGDHSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11059788-B2 Streamlined syntheses of fluoroquinolones VIRGINIA COMMONWEALTH UNIVERSITY (US) 2021-07-13 US disclosed
US-11059788-B2 Streamlined syntheses of fluoroquinolones VIRGINIA COMMONWEALTH UNIVERSITY (US) 2021-07-13 US disclosed
US-20200123111-A1 STREAMLINED SYNTHESES OF FLUOROQUINOLONES VIRGINIA COMMONWEALTH UNIVERSITY 2020-04-23 US disclosed
US-20200123111-A1 STREAMLINED SYNTHESES OF FLUOROQUINOLONES VIRGINIA COMMONWEALTH UNIVERSITY 2020-04-23 US disclosed
EP-3638648-A2 STREAMLINED SYNTHESES OF FLUOROQUINOLONES Virginia Commonwealth University (US) 2020-04-22 EP disclosed
CN-111032622-A Streamlined synthetic fluoroquinolones 弗吉尼亚联邦大学 2020-04-17 CN disclosed
WO-2018231747-A2 STREAMLINED SYNTHESES OF FLUOROQUINOLONES VIRGINIA COMMONWEALTH UNIVERSITY (US) 2018-12-20 WO disclosed
US-10087165-B2 Fluoroquinolones and use thereof to treat bacterial infections SORBONNE UNIVERSITE (FR) 2018-10-02 US disclosed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US disclosed
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS UNIVERSITÉ PIERRE ET MARIE CURIE - PARIS 6 (UPMC) (FR) 2017-05-25 US disclosed
EP-2957561-A1 Novel fluoroquinolones and use thereof to treat bacterial infections Université Paris 6 Pierre et Marie Curie UPMC (FR) 2015-12-23 EP disclosed
EP-1401829-B1 NOVEL HETEROCYCLIC ANTIBACTERIAL COMPOUNDS MICROBIOTIX INC (US) 2012-08-22 EP disclosed
US-6777420-B2 A URACIL COMPOUNDS AS ENZYME INHIBITORS, INHIBIT BACTERIAL DNA POLYMERASE, TREATING BACTERIAL DISEASES MICROBIOTIX, INC. 2004-08-17 US disclosed
US-20030181719-A1 Novel heterocyclic antibacterial compounds MICROBIOTIX, INC. 2003-09-25 US disclosed
WO-2001002365-A1 CIPROFLOXACIN HYDRATES AND METHOD FOR THEIR PRODUCTION BAYER AKTIENGESELLSCHAFT (DE) 2001-01-11 WO disclosed
US-5914401-A Methods for the manufacture of quinolone carboxylic acids derivatives and intermediates thereof APOTEX, INC. (CA) 1999-06-22 US disclosed
US-5281596-A Treatment with 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-ethylpiperazino)quinoline-3 -carboxylic acid or salt BAYER AKTIENGESELLSCHAFT (DE) 1994-01-25 US disclosed
EP-0238814-B1 ANTIBACTERIAL MEDICAMENTS FOR FISH BAYER AG (DE) 1992-06-24 EP disclosed
EP-0238814-A2 Antibacterial medicaments for fish BAYER AG (DE) 1987-09-30 EP disclosed
CN-87100799-A ANTIBACTERIAL DRUGS FOR FISH 1987-09-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181719-A1 Novel heterocyclic antibacterial compounds TOP1, TOP2A, TOP2B KDM4E 2689/4885ALDH1A1 2897/4885HPGD 707/4885
US-10087165-B2 Fluoroquinolones and use thereof to treat bacterial infections CFTR, NQO2, FPR1 KDM4E 3086/4885ALDH1A1 4095/4885HPGD 755/4885
US-20170144992-A1 NOVEL FLUOROQUINOLONES AND USE THEREOF TO TREAT BACTERIAL INFECTIONS CFTR, IRF3, FPR1 KDM4E 3242/4885ALDH1A1 4490/4885HPGD 1216/4885
US-20200123111-A1 STREAMLINED SYNTHESES OF FLUOROQUINOLONES NRAS, QARS1, BLM KDM4E 1424/4885ALDH1A1 3504/4885HPGD 1095/4885
US-11059788-B2 Streamlined syntheses of fluoroquinolones NRAS, QARS1, BLM KDM4E 1424/4885ALDH1A1 3504/4885HPGD 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.